UNSPSC 51351605: Estradiol or oestradiol

This classification denotes an estrogen with the molecular formula C18H24O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4TI98Z838E, chemically known as estra-1,3,5(10)-triene-3,17-diol (17.beta.)- but generally known as estradiol, which bears US NIH Compound Identifier 450. European Medicines Agency schedules Estradiol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07242MIG. The term ESTRADIOL is an International Non-Proprietary Name.

UNSPSC 51351605 Estradiol or oestradiol, a Commodity code, covers the procurement of this hormone replacement therapy agent by state and local health systems, correctional facilities, and other public entities. State and local governments buy estradiol and related hormone products through pharmaceutical cooperative purchasing vehicles that aggregate demand across multiple jurisdictions and consolidate sourcing with authorized wholesale distributors. The work involves manufacturers and suppliers submitting pricing, product specifications including National Drug Codes (NDCs), and compliance documentation to establish blanket contracts that serve participating facilities over multi-year terms, with pricing weighted heavily in the evaluation against administrative and operational requirements such as cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, EDI capability, and insurance thresholds.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities across Minnesota and Oregon. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and demonstrate pricing flexibility through fixed price, net price formats (NF30, NF60, NF90), or WAC-minus structures, with price competitiveness weighted at 75 percent of the evaluation score. The RFP requires a 3 percent administrative fee on all contract purchases, compliance with FDA requirements, comprehensive insurance coverage including $5 million commercial general liability per occurrence, and performance penalties ranging from $200 to $1,500 per violation for late reporting or missed onboarding timelines. Contract terms span two years for new responders with optional MMCAP extensions, and incumbent responders' amendments align with existing expiration dates through June 30, 2028.